The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > October 15, 2025
Daily News
October 15, 2025
- ASKA Keeps Defense Policy in Place as Dalton Dispute Persists
October 15, 2025
- Sanofi, NIID Sign MOU on Infectious Disease Collaboration
October 15, 2025
- Astellas’ Vyloy Combo Fails to Improve Survival in PII Pancreatic Cancer Study
October 15, 2025
- Mitsubishi Tanabe Files Uplizna Label Expansion for gMG in Japan
October 15, 2025
- Novo, Sumitomo Extend Co-Promotion Partnership to Wegovy
October 15, 2025
- Kite Looks to Expand Japan CAR-T Footprint, Boosts Supply Infrastructure
October 15, 2025
- Moderna Launches LP.8.1-Adapted Spikevax for Ages 6 Months to 11 Years
October 15, 2025
- Komeito’s Exit from Ruling Coalition Casts Uncertainty over Japan’s Drug Policy
October 15, 2025
- Japan to Continue Subsidies for Domestic Biosimilar Production: MHLW Official
October 15, 2025
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…